Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 640 results for "clopidogrel"

Market Research Report on Global and Chinese Clopidogrel bisul...

is a professional and in-depth market survey on Global and Chinese Clopidogrel bisulfate industry. The report firstly reviews the basic information of Clopidogrel bisulfate including its classification, application and manufacturing technology; The ... Individual.com, 9 hours ago

2 images for "clopidogrel"

MDLinx, 2 weeks ago
MDLinx, 2 weeks ago

Clopidogrel-PPI Interaction Questioned in Meta-analysis

DURHAM, NC — There is a disconnect between results derived from observational studies examining the safety of using proton-pump inhibitors (PPIs) with dual antiplatelet therapy and the results obtained from randomized, controlled clinical ...
 Dermatology Online Journal22 hours ago

Human medicines European public assessment report (EPAR): DuoCover, clopidogrel / acetylsalicylic acid, Revision: 10, Authorised

This is a summary of the European public assessment report (EPAR) for DuoCover. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 week ago Tianma's Clopidogrel got CEP certificate  Healthoo.com1 month ago

Pending EC decision: Clopidogrel ratiopharm, clopidogrel, Opinion date: 18-Dec-2014

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Clopidogrel ratiopharm , 75 mg, film-coated tablet intended for prevention of ...
 European Medicines Agency1 month ago Pending EC decision: Zontivity, vorapaxar, Opinion date: 20-Nov-2014  European Medicines Agency2 months ago

Vorapaxar and Clopidogrel After Non-ST ACS

Results From the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome Trial Pierluigi Tricoci, MD, PhD, Yuliya Lokhnygina, PhD, Zhen Huang, MS, Frans Van de Werf, MD, Jan H. Cornel, MD, Edmond Chen, MD, Lars ...
 General Medicine eJournal1 month ago Room for Improvement in Acute Coronary Syndrome Treatment  Pharmacy Times1 week ago The year in cardiology 2014: acute coronary syndromes  Eurheartj Oxford Journals3 weeks ago Studies from AstraZeneca Describe New Findings in Acute Coronary Syndrome (Causes of mortality with ticagrelor compared with clopidogrel in acute...  4 Traders1 month ago

NICE recommends Xarelto (rivaroxaban) as an effective treatment option for reducing risk of secondary events in ACS

NICE FAD recommends 2.5mg Xarelto twice daily in combination with aspirin alone or aspirin plus clopidogrel or ticlopidine, as an option for secondary prevention following ACS in patients with elevated cardiac biomarkers, without prior stroke or ...
 FirstWord Pharma6 days ago NICE Recommends Xarelto®▼ (rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary …  Yahoo! Finance5 days ago NICE Recommends Xarelto(R)a- 1/4 (rivaroxaban) as an Effective Treatment Option for Reducing Risk of Secondary Events in ACS[1]  Individual.com5 days ago
[x]  

Information Update - Health Canada reviewing possible safety concerns with certain long-term antiplatelet (blood thinner) therapy; Benefits of treatment still outweigh potential risks

OTTAWA, Nov. 18, 2014 Clopidogrel and prasugrel reduce the risk of blood clots in patients who have had a heart attack, stroke or related blood clotting diseases. Dual antiplatelet therapy is the use of a blood thinner in combination with ASA ...
 BusinessWeek2 months ago Health Canada to review evidence on the safety of long-term use of prescription blood-thinners  News-Medical.Net2 months ago Health Canada reviewing possible safety concerns with certain long-term antiplatelet (blood thinner) therapy; Benefits of treatment still outweigh potential risks  Health Canada2 months ago
[x]  

Class 2 Drug Alert (Action within 48 hours): Acino Pharma GmbH - Clopidogrel 75 mg Tablets - EL (10)A/09

DRUG ALERT CLASS 2 MEDICINES RECALL Action within 48 hours Pharmacy and wholesaler level recall 30 March 2010 EL (10)A/09 Our ref: MDR 63-03/10 Dear Healthcare Professional, Acino Pharma GmbH Clopidogrel 75mg Tablets (Stock distributed in both ...
 MHRA1 day ago

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting

Methods Study design ISAR-SAFE is an investigator-initiated, international, multicentre, randomized, double-blind, placebo-controlled trial. The authors are solely responsible for the design, conduct, data analyses as well as drafting and editing ...
 European Heart Journal4 days ago

clopidogrel bisulfate, Plavix

Pharmacy Author: Omudhome Ogbru, PharmD Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University ...
 MedicineNet.com4 weeks ago Advancing pharmacogenomics in pharmacy practice  Pharmacist.com5 days ago Pursuing pharmacy practice in pharmacogenomics  Pharmacist.com5 days ago Pharmacogenomics: Emerging opportunity for pharmacists  Pharmacist.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less